Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
Imfinzi plus Imjudo combo significantly improved five-year overall survival rates in unresectable hepatocellular carcinoma patients compared to sorafenib, with 19.6% surviving vs. 9.4%.
Related Clinical Trials
Reference News
Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
Imfinzi plus Imjudo combo significantly improved five-year overall survival rates in unresectable hepatocellular carcinoma patients compared to sorafenib, with 19.6% surviving vs. 9.4%.